Ftse Mib
34.315,24
0,00%
DAX
20.246,37
-0,33%
S&P 500
6.050,61
-0,39%
NASDAQ
20.109,06
-0,32%
Bitcoin
103.645,74
-2,36%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Arcturus Therapeutics Holdings Inc (ARCT) Arcturus Therapeutics Holdings Inc (ARCT) Notizie

Arcturus Therapeutics Holdings Inc

ARCT
15,97
-0,27 (-1,66%)
18 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
16/12/202422:01BWArcturus Therapeutics to Present at the 43rd Annual J.P...
26/11/202422:01BWArcturus Therapeutics to Attend Upcoming Investor..
19/11/202402:00BWArcturus Therapeutics to Present at Jefferies London..
14/11/202407:00BWMeiji Seika Pharma Announces Investment in ARCALIS, Inc.
11/11/202422:01BWArcturus Therapeutics Receives Clearance from FDA to Begin..
07/11/202422:25EDGAR2Form 8-K - Current report
07/11/202422:01BWArcturus Therapeutics Announces Third Quarter 2024 Financial..
31/10/202421:01BWArcturus Therapeutics to Report Third Quarter Financial..
30/9/202414:00BWSelf-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior..
13/9/202414:15PRNUSJapan's Ministry of Health, Labor and Welfare Approves CSL..
13/9/202414:00BWJapan’s Ministry of Health, Labor and Welfare Approves CSL..
03/9/202414:30BWArcturus Therapeutics Receives Clearance of an..
27/8/202423:00BWArcturus Therapeutics to Attend Upcoming Investor &..
13/8/202413:54EDGAR2Form 8-K - Current report
05/8/202422:50EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
05/8/202422:09EDGAR2Form 8-K - Current report
05/8/202422:01BWArcturus Therapeutics Announces Second Quarter 2024..
01/8/202422:01BWArcturus Therapeutics to Present at Canaccord Genuity 44th..
19/7/202401:30BWArcturus Therapeutics to Report Second Quarter Financial..
17/7/202423:27EDGAR2Form S-8 - Securities to be offered to employees in employee..
01/7/202422:01BWArcturus Therapeutics Provides Updates for Ornithine..
20/6/202414:00BWArcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to..
19/6/202403:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/6/202403:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202422:30EDGAR2Form 8-K - Current report
07/6/202416:30BWArcturus Therapeutics Presents New Clinical Data at 47th..
28/5/202412:30BWArcturus Therapeutics Announces Positive Development for..
22/5/202413:00GLOBEAchilles Therapeutics Announces Research Collaboration with..
20/5/202414:30BWNature Communications Publishes Pivotal Data Demonstrating..
15/5/202422:01BWArcturus Therapeutics to Attend Upcoming Investor &..
08/5/202422:17EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202422:05EDGAR2Form 8-K - Current report
08/5/202422:01BWArcturus Therapeutics Announces First Quarter 2024 Financial..
25/4/202422:01BWArcturus Therapeutics to Report First Quarter Financial..
07/3/202422:05EDGAR2Form 8-K - Current report
07/3/202422:01BWArcturus Therapeutics Announces Fourth Quarter and Fiscal..
26/2/202415:00BWArcturus Therapeutics to Present at the Barclays 26th Annual..
23/2/202422:05EDGAR2Form 8-K - Current report
22/2/202414:30BWArcturus Therapeutics Receives Orphan Medicinal Product..
20/2/202415:00BWArcturus Therapeutics to Report Fourth Quarter and Full Year..
05/2/202414:30PRNUSNew COVID-19 sa-mRNA Results from CSL and Arcturus..
21/12/202314:00BWCSL and Arcturus Therapeutics’ ARCT-154 Demonstrates..
20/12/202302:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 16,85 Min: 15,5546 Max: 16,85
Chiusura: 16,24

La tua Cronologia

NASDAQ
ARCT
Arcturus Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network